RxDoctor Payments Data

Rodney Short, MD

Neurology · Davenport, IANPI 1184602013

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,763 of the $5,704 with a category attached, or 66.0%. 49 manufacturers reported payments, led by Eisai Inc. at 43.0% of the total.

$5,704in general payments, 2019–2025

Across 174 payments — averaging $32.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$2K
  • AbbVie$348
  • Teva Pharmaceuticals USA, Inc.$286
  • Lundbeck LLC$233
  • Lilly USA, LLC$229
  • Genentech USA, Inc.$213
  • plus $2K from 43 others

What the payments were for

  • Consulting fees$1,76031%
  • Speaking & faculty fees$150%
  • Food & beverage$3,76366%
  • Education$1663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,704 in reported general payments places this provider in the 80th percentile of 132 neurology providers in Iowa.

See all neurology providers in Iowa

Medicare billing

Part B allowed, 2024
$60,199
Medicare patients
324
Services billed
2,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate12$67,652
Nurtec OdtRimegepant Sulfate55$66,871
Aimovig AutoinjectorErenumab-Aooe24$22,195
RytaryCarbidopa/Levodopa13$16,097
LyricaPregabalin16$9,490
Carbidopa-LevodopaCarbidopa/Levodopa210$7,603
Entacapone25$7,284
Galantamine ErGalantamine Hbr50$5,283
Rasagiline Mesylate26$5,230
Gabapentin253$5,070
Rivastigmine12$4,664
Levetiracetam145$4,620
Topiramate128$3,749
Donepezil Hcl435$3,708
RivastigmineRivastigmine Tartrate30$3,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Lyrica$47$76,36171 claims
Teva Pharmaceuticals USA, Inc.Copaxone$286$67,65212 claims
Amneal Pharmaceuticals LLCRytary$152$16,09713 claims
Upsher-smith Laboratories LLCTopiramate$22$3,749128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 132 neurology providers in Iowa.

Other neurology in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →